XML 11 R1.htm IDEA: XBRL DOCUMENT v3.25.3
Cover
 12 Months Ended
Jun. 30, 2025
shares
Document Information [Line Items]  
Document Type 20-F
Amendment Flag false
Document Period End Date Jun. 30, 2025
Document Fiscal Year Focus 2025
Document Fiscal Period Focus FY
Entity Registrant Name Kazia Therapeutics Limited
Entity Central Index Key 0001075880
Current Fiscal Year End Date --06-30
Entity Well-known Seasoned Issuer No
Entity Current Reporting Status Yes
Entity Filer Category Non-accelerated Filer
Entity Emerging Growth Company false
Entity Voluntary Filers No
Entity Shell Company false
Entity Interactive Data Current Yes
Document Transition Report false
Document Annual Report true
Document Shell Company Report false
Entity Address, Address Line One Three International Towers, Level 24, 300 Barangaroo Avenue
Entity Address, City or Town Sydney
Entity Address, Postal Zip Code 2000
Entity Address Country AU
Document Registration Statement false
Document Accounting Standard International Financial Reporting Standards
Entity Common Stock, Shares Outstanding 809,418,734
Entity Incorporation, State or Country Code C3
Entity File Number 0-29962
Title of 12(b) Security American Depositary Shares, each representing five-hundred Ordinary Shares*
Trading Symbol KZIA
Security Exchange Name NASDAQ
ICFR Auditor Attestation Flag false
Auditor Name BDO Audit Pty Ltd
Auditor Firm ID 2256
Auditor Location Sydney, Australia
Document Financial Statement Error Correction [Flag] false
Business Contact [Member]  
Document Information [Line Items]  
Contact Personnel Name John Friend, M.D.
Contact Personnel Email Address John.Friend@kaziatherapeutics.com
Entity Address, Address Line One Three International Towers, Level 24, 300 Barangaroo Avenue
Entity Address, City or Town Sydney
Entity Address, Postal Zip Code 2000
Entity Address Country AU
Country Region 61
City Area Code 2
Local Phone Number 9472-4101